Immuron achieves record monthly Travelan® sales
13 Setembro 2023 - 7:00AM
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and
globally integrated biopharmaceutical company is pleased to
announce record monthly sales (unaudited net sales) of its
over-the-counter gastrointestinal and digestive health immune
supplement Travelan®.
Immuron previously reported (August 9, 2023)
that short term stock outages of Travelan® in some wholesalers and
pharmacies in the June 2023 quarter was resolved following receipt
of GMP Clearance from the Therapeutic Goods Administration (TGA).
Immuron has since supplied product to wholesalers who in turn have
supplied retail pharmacies.
Sales of Travelan® increased by 7984% in August
2023 to AUD $1.18 M, compared to AUD $14,581 in August 2022. This
increase partially reflects 3 months of backorders accrued while
awaiting GMP Clearance from the TGA.
Immuron anticipates continued demand for replenishment of
Travelan® as retail pharmacies sell to consumers. Short term
resident returns in July 2023 were 48% higher than July 2022 and
approaching pre-pandemic levels (89% of April 2019)1.
Australian Bureau of Statistics resident returns – short term
compares resident returns each month by destination country.
Analysis is undertaken on short-term trips (less than one year).
Indonesia was the most popular destination country, accounting for
14% of all resident returns.1
Immuron previously reported (July 5, 2023) that it had shipped
inventory to Amazon for launch in USA. The Amazon launch has been
progressing well. Sales via Amazon in August exceeded those to our
largest B2B customer, Passport Health. We are now entering the low
travel season in USA. Immuron anticipates sales to grow strongly
closer to the peak spring / summer travel period.
-
https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latest-release
This release has been authorised by the directors of Immuron
Limited.
COMPANY
CONTACT:Steven
LydeamoreChief Executive OfficerPh: +61 (0)3 9824
5254info@immuron.com |
About Travelan®
Travelan® is an orally administered passive
immunotherapy that prophylactically reduces the likelihood of
contracting travelers’ diarrhea, a digestive tract disorder that is
commonly caused by pathogenic bacteria and the toxins they produce.
Travelan® is a highly purified tabletized preparation of hyper
immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization
and the pathology associated with travelers’ diarrhea. In
Australia, Travelan® is a listed medicine on the Australian
Register for Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travelers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licensed natural health product (NPN 80046016) and
is indicated to reduce the risk of Travelers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and
occasionally bloody) stools, abdominal cramping, bloating, and
fever, Enteropathogenic bacteria are responsible for most cases,
with enterotoxigenic Escherichia coli (ETEC) playing a dominant
causative role. Campylobacter spp. are also responsible for a
significant proportion of cases. The more serious infections with
Salmonella spp. the bacillary dysentery organisms belonging to
Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers’ diarrhea as they may be contracted
while travelling and initial symptoms are often
indistinguishable.
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases.
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Immuron (NASDAQ:IMRN)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024